

Towards better outcomes in multiple sclerosis by
addressing policy change:

The International MultiPLE Sclerosis Study (IMPrESS)

<http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/IMPRESS-Report-March-2016.pdf>

EMSP, Oslo 2016

**Panos Kanavos, Michela Tinelli, Olina Efthymiadou, Erica Visintin,
Federico Grimaccia, Jean Mossman**




The IMPRESS (International-MultiPLE-Sclerosis-Study)

Online survey of 246 people with MS

- France 39%
- USA 29%
- Romania 18%
- UK 10%
- Germany 4%
- RRMS 66%
- SPMS 11%
- PPMS 10%
- Unknown 13%
- Differences between countries for:
 - Total cost
 - Direct medical costs
 - Indirect costs
 - Quality of life (measured by EQ-5D)

Reduction in quality of life



Health status: Aspects identified as having a big impact by PWMS

Fatigue and weakness	54%
Mobility	54%
Balance problems and dizziness	49%
Usual activities	48%
Pain/discomfort	42%
Bladder problems	38%

These are the top six aspects that respondents believed a new MS treatment should keep under control

Choosing disease modifying treatments: the most important three attributes

What clinicians said	What clinicians said drove PWMS' decisions	What PWMS said
Effectiveness Safety Tolerability	Effectiveness Safety Tolerability	Convenience (25%) Doctor's advice (19%) Other* (19%) Tolerability (17%) Effectiveness (14%)

* Side effects (i.e. safety), do not currently take/want to take any medicines

There is an urgent need to achieve better outcomes for PWMS

The evidence suggests that this is possible if policy makers address the following issues.

- **Diagnosis, treatment and management goals should be set to provide the best health outcome for every person with MS**
- **(Further) robust evidence should be generated and used in order to make appropriate decisions about care management in MS strategies**
- **Improve the responsiveness of health care systems to new evidence on MS**

Next steps

- Expand the number of countries and participants
- If you are interested in participating, contact:
Michela Tinelli
M.Tinelli@lse.ac.uk

Thanks to:

- All who completed the questionnaire
- European Multiple Sclerosis Platform, MS Society UK, MS Trust UK, National Multiple Sclerosis Society, the Romanian Association of Multiple Sclerosis, the Rocky Mountain Multiple Sclerosis Center and Foundation ARSEP - French MS Research Society - who facilitated data collection.
- Rozalina Lapadatu, Alessandra Ferrario, Elena Nicod and Olivier Wouters for translating the questionnaires.
- Birgit Bauer and Rozalina Lapadatu for additional insights and support in the development of the questionnaires and facilitating their distribution to respondents.
- F. Hoffmann-La Roche provided the sponsorship that allowed the LSE to carry out this research.